A股異動 | 普洛藥業(000739.SZ)漲超4% 2020年度純利同比增長47.58%
格隆匯3月12日丨普洛藥業(000739.SZ)現報25.99元,漲4.04%,暫成交4.9億元,最新總市值306億元。普洛藥業昨日盤後發佈2020年年度報吿稱,期內實現營業收入78.80億元,同比增長9.28%;歸屬於上市公司股東的淨利潤8.17億元,同比增長47.58%;基本每股收益0.6930元,擬每10股派發現金紅利2.43元(含税)。經過近二十年的深耕細作與積累,公司CDMO業務具有“化學合成+生物發酵”雙輪驅動的技術能力和“多客户、多產品”的競爭優勢。期內,公司CDMO業務強勁增長,實現營業收入10.55億元,較上年同期增長46.14%;實現毛利率41.62%,較上年同期增加4.33個百分點。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.